Condition
Hepatocellular Carcinoma With PVTT
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 4 (1)
Trial Status
Not Yet Recruiting1
Recruiting1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06646198Phase 2RecruitingPrimary
TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension
NCT06210334Phase 2Not Yet RecruitingPrimary
HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)
NCT01350206Phase 4UnknownPrimary
Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis
Showing all 3 trials